GLP-1R/GIPR agonist-1

GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide) . GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) [1].

Product Specifications

UNSPSC

12352209

Target

GLP Receptor; Insulin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Protein Tyrosine Kinase/RTK

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/glp-1r-gipr-agonist-1.html

Solubility

10 mM in DMSO

Smiles

O=C(NC(CCC(NCCOCCOCC(NCCOCCOCC(NCCCCC(NC([C@H](C)NC([C@H](C)NC([C@H](CCCNC(N)=N)NC([C@H](CCCCN)NC([C@H](CC(O)=O)NC([C@@H](NC(C(C)(C)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC1=CC=C(C=C1)O)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC2=CC=CC=C2)NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(N)=O)NC(C(C)(C)NC([C@H](CC3=CNC=N3)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC5=CNC6=CC=CC=C56)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(NCC(NCC(N7[C@@H](CCC7)C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N8[C@@H](CCC8)C(N9[C@@H](CCC9)C(N%10[C@@H](CCC%10)C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C(O)=O)CCCCCCCCCCCCCCCCC(O)=O

Molecular Formula

C220H342N55O69

Molecular Weight

4861.38

References & Citations

[1]Liu C, et al. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent[J]. Bioorganic Chemistry, 2021, 106: 104492.